Material solutions for delivery of CRISPR/Cas-based genome editing tools: Current status and future outlook
The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
Abstract Clustered regularly interspaced short palindromic repeat (CRISPR)/associated protein (CRISPR/Cas) system is an adaptable immune mechanism used by many bacteria to protect themselves from invading nucleic acids, and it has been recently exploited as an efficient tool for site-specific, programmable genome editing in both single cells and whole organisms with a precise manner. CRISPR/Cas system has been shown its great potentials for a wide range of biomedical applications, such as transcriptional control, epigenetic modification, genome-wide screening and chromosomal imaging, and treatment of genetic disorders. Despite these excitements, the shortage of delivery materials that can deliver genome editing tools (including plasmid DNA, mRNA, and ribonucleoprotein) represents one of the major challenges for successful CRISPR/Cas-based genome editing. This review seeks to provide a comprehensive overview of different types of carriers ranging from classic drug delivery materials to advanced drug delivery systems that can transport CRISPR/Cas systems and mediate genome editing at the targeted loci. The challenges and future prospects of the delivery materials for optimizing the CRISPR delivery system for clinical translations are also highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Hydrogels for biomedical applications
Hoffman, A. S. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.010 · Cited by 3,396
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Gasiunas, G., Barrangou, R., Horvath, P., & Siksnys, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208507109 · Cited by 2,769
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Cited by
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
Wang, D., Zhang, F., & Gao, G. (2020) · Cell · doi:10.1016/j.cell.2020.03.023 · Cited by 527
Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?
Vallet-Regí, M., Schüth, F., Lozano, D., Colilla, M., & Manzano, M. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00659b · Cited by 507
Overcoming blood–brain barrier transport: Advances in nanoparticle-based drug delivery strategies
Ding, S., Khan, A. I., Cai, X., Song, Y., Lyu, Z., Du, D., Dutta, P., & Lin, Y. (2020) · Materials Today · doi:10.1016/j.mattod.2020.02.001 · Cited by 440
Wan, T., Zhong, J., Pan, Q., Zhou, T., Ping, Y., & Liu, X. (2022) · Science Advances · doi:10.1126/sciadv.abp9435 · Cited by 299
Self-citation
Metadata
- Authors
- Wan, T., Niu, D., Wu, C., Xu, F.-J., Church, G., & Ping, Y.
- Venue
- Materials Today
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 26
- Pages
- 40-66
- ISSN
- 1369-7021 (ISSN-L)
- OpenAlex
- W2908648691
- Cited by
- 117
- References
- 76
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Material solutions for delivery of CRISPR/Cas-based genome editing tools: Current status and future outlook. https://app.cochat.ai/papers/10.1016/j.mattod.2018.12.003
- The paper
- Wan, T., Niu, D., Wu, C., Xu, F.-J., Church, G., & Ping, Y. (2019). Material solutions for delivery of CRISPR/Cas-based genome editing tools: Current status and future outlook. Materials Today. https://doi.org/10.1016/j.mattod.2018.12.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.